Hologic revealed that Steve MacMillan, the company’s longtime chairman, president, and CEO decided to retire when its go-private transaction with Blackstone and TPG closes.

The $18.3 billion merger deal was first announced in October 2025. The company said that all required regulatory approvals have been received for the transaction and it’s expected to close on or about April 7, 2026.

“Hologic’s board of directors, and all the Company’s stakeholders, owe a debt of gratitude to Steve, one of the most respected leaders in the medical technology industry,” said Amy Wendell, Hologic’s lead independent director. “He forged a dramatic turnaround shortly after joining the Company, led us through years of consistent growth, drove our unprecedented response to the COVID pandemic, and is guiding us through a successful go-private transaction.”

In MacMillan’s 12-plus years with Hologic, the company’s revenue grew 65%. Its non-GAAP earnings per share (EPS) rose 184%, its share price increased 241%, and its workforce expanded by over 1,500 employees. The company’s next CEO is anticipated to be revealed when the transaction is complete.

MacMillan (62) joined Hologic as president and CEO in December 2013. He was elected chairman in 2015. From 2005 to 2012, he was president and CEO of Stryker, where he had served as president since 2003.

Before that, he was a senior exec at Pharmacia and Johnson & Johnson. MacMillan began his career at Procter and Gamble in 1985. He’s served on the boards of Davidson, Illumina (non-executive chair), AdvaMed, Alere, Boston Scientific and Texas Instruments.

“Leading Hologic has been the greatest honor and privilege of my career,” MacMillan said. “I’m immensely grateful to the customers and patients who trusted us, the board and investors who supported us, and especially the employees who made all our accomplishments possible. I know they will make even greater contributions to women’s health as a private firm owned by Blackstone and TPG.”